CytomX Therapeutics, Inc.

Pharmaceutical Preparations

CTMX Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001501989 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$716.89M
217,899,284 shares Covers every share class this company has on file.
Insiders on file
3
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$10.58M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
1.48%
insider-held value divided by market capitalisation

What CytomX Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$76.20M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$17.37M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
69
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at CytomX Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against CytomX Therapeutics, Inc..
Insider Reported role Shares Value Last action
Officers 2
Marcia Belvin Marcia Belvin SVP 300,760 $1.12M S Open-market sale Mar 17, 2026 position reported
Christopher Ogden CFO 296,948 $1.10M S Open-market sale Jun 15, 2026 position reported
Officers who also sit on the board 1
Sean A McCarthy Sean A McCarthy CEO 2,253,129 $8.36M S Open-market sale Mar 17, 2026 position reported

Recent insider transactions

Of the 32 rows we hold, 0 are open-market purchases and 15 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for CytomX Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jun 15, 2026 Christopher Ogden S Open-market sale 1,624 $3.05 $5.0K SEC filing ↗
Mar 17, 2026 Marcia Belvin S Open-market sale 31,492 $6.42 $202.2K SEC filing ↗
Mar 17, 2026 Christopher Ogden S Open-market sale 19,323 $6.42 $124.1K SEC filing ↗
Mar 17, 2026 Sean A McCarthy S Open-market sale 118,969 $6.42 $763.8K SEC filing ↗
Feb 2, 2026 Marcia Belvin A Grant or award 60,000 $0.00 $0 SEC filing ↗
Feb 2, 2026 Christopher Ogden A Grant or award 90,000 $0.00 $0 SEC filing ↗
Feb 2, 2026 Sean A McCarthy A Grant or award 210,000 $0.00 $0 SEC filing ↗
Nov 6, 2025 Sean A McCarthy S Open-market sale 101,793 $4.54 $462.1K SEC filing ↗
Jun 16, 2025 Marcia Belvin S Open-market sale 13,884 $2.69 $37.3K SEC filing ↗
Jun 16, 2025 Christopher Ogden S Open-market sale 10,614 $2.69 $28.6K SEC filing ↗
Jun 16, 2025 Sean A McCarthy S Open-market sale 55,511 $2.69 $149.3K SEC filing ↗
Jun 13, 2025 Marcia Belvin M Option exercise or conversion 37,500 $0.00 $0 SEC filing ↗
Jun 13, 2025 Christopher Ogden S Open-market sale 1,641 $2.95 $4.8K SEC filing ↗
Jun 13, 2025 Christopher Ogden M Option exercise or conversion 37,500 $0.00 $0 SEC filing ↗
Jun 13, 2025 Sean A McCarthy M Option exercise or conversion 150,000 $0.00 $0 SEC filing ↗
Mar 18, 2025 Marcia Belvin S Open-market sale 19,512 $0.60 $11.7K SEC filing ↗
Mar 18, 2025 Christopher Ogden S Open-market sale 8,551 $0.60 $5.1K SEC filing ↗
Mar 18, 2025 Sean A McCarthy S Open-market sale 37,656 $0.60 $22.6K SEC filing ↗
Feb 4, 2025 Marcia Belvin A Grant or award 30,000 $0.00 $0 SEC filing ↗
Feb 4, 2025 Marcia Belvin A Grant or award 35,000 $0.00 $0 SEC filing ↗
Feb 4, 2025 Marcia Belvin A Grant or award 57,500 $0.00 $0 SEC filing ↗
Feb 4, 2025 Christopher Ogden A Grant or award 57,500 $0.00 $0 SEC filing ↗
Feb 4, 2025 Christopher Ogden A Grant or award 44,000 $0.00 $0 SEC filing ↗
Feb 4, 2025 Sean A McCarthy A Grant or award 180,000 $0.00 $0 SEC filing ↗
Feb 4, 2025 Sean A McCarthy A Grant or award 195,000 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from CytomX Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from CytomX Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.